Dueling Commentaries In JAMA Revisit US FDA Approval Of Abiomed’s Impella
This article was originally published in Clinica
Is the US FDA’s 515 Program Initiative for so-called “pre-amendment” technologies, leading to approvals of high-risk devices, based on flawed evidence? This question is addressed by two expert commentaries, posted online by JAMA Cardiology on March 9, that review the US FDA’s 2015 approval of Abiomed’s Impella 2.5 percutaneous ventricular assist device under the 515 Program Initiative.
You may also be interested in...
Abiomed is trying to counter the negative publicity created by the recent publication of retrospective studies showing higher costs and worse outcomes in coronary intervention cases with Impella than in comparable procedures with intra-aortic balloon pumps. The company insists this analysis is deeply flawed.
The Israeli company raised $16m to support its Augmented Respiration Technology, a novel approach for delivering oxygen directly into the venous system. The company expects to earn FDA clearance for first product by 2023.
Abbott expects the ongoing recovery of medical procedure volumes to continue even as new virus variants are causing COVID-19 cases to increase in some geographies.